Bridgebio Pharma Inc Earnings Dividend

Bridgebio Pharma Inc’s revenue jumped 66.78% since last year same period to $194.52Mn in the Q1 2026. On a quarterly growth basis, Bridgebio Pharma Inc has generated 26.16% jump in its revenue since last 3-months.

Bridgebio Pharma Inc’s net profit jumped 2.02% since last year same period to $-164.04Mn in the Q1 2026. On a quarterly growth basis, Bridgebio Pharma Inc has generated 16.83% jump in its net profits since last 3-months.

Bridgebio Pharma Inc’s net profit margin jumped 41.25% since last year same period to -84.33% in the Q1 2026. On a quarterly growth basis, Bridgebio Pharma Inc has generated 34.08% jump in its net profit margins since last 3-months.

Bridgebio Pharma Inc’s earning per share (EPS) estimates for the current quarter stand at -0.64 - a 10.18% jump from last quarter’s estimates.

Bridgebio Pharma Inc’s earning per share (EPS) estimates for the current year stand at -0.64.

Bridgebio Pharma Inc’s earning per share (EPS) jumped 15.05% since last year same period to -0.84 in the Q1 2026. This indicates that the Bridgebio Pharma Inc has generated 15.05% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Bridgebio Pharma Inc’s return on assets (ROA) stands at -0.34.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Bridgebio Pharma Inc’s return on equity (ROE) stands at -17.9.